High Risk of Heart Failure Associated with Desmoglein-2 Mutations Compared to Plakophilin-2 Mutations in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia

Abstract

In this multicentre cohort, DSG2 mutation carriers were found to be at high risk of end-stage HF compared to PKP2 mutation carriers, supporting careful haemodynamic monitoring of these patients. The benefit of early HF treatment needs to be assessed in DSG2 carriers.